Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15820536 | 0.79 | FFAR4 (0.43) | ALDH1A1SMN1; SMN2HSD17B10MEN1KMT2A | |
| SCHEMBL17273953 | 0.77 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL17273951 | 0.77 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL15839472 | 0.76 | TDP1 (0.41) | ALDH1A1SMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL15821609 | 0.73 | GCK (0.50) | ALDH1A1SMN1; SMN2HTT | |
| SCHEMBL17278957 | 0.73 | GCK (0.43) | MEN1KMT2A | |
| SCHEMBL7799881 | 0.72 | SRD5A1 (0.60) | HIF1A | |
| SCHEMBL7799877 | 0.72 | SRD5A1 (0.60) | HIF1A | |
| SCHEMBL15819998 | 0.70 | HSD17B10 (0.46) | ALDH1A1SMN1; SMN2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2909176 | 0.70 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2931734-B1 | NOVEL GLUCOKINASE ACTIVATOR COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT | MERCK SHARP & DOHME (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-2931734-B1 | NOVEL GLUCOKINASE ACTIVATOR COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT | MERCK SHARP & DOHME (US) | 2020-12-02 | — | — | EP | disclosed |
| US-9453038-B2 | Glucokinase activator compounds, compositions containing such compounds, and methods of treatment | MERCK SHARP & DOHME CORP. (US) | 2016-09-27 | — | — | US | disclosed |
| US-9453038-B2 | Glucokinase activator compounds, compositions containing such compounds, and methods of treatment | MERCK SHARP & DOHME CORP. (US) | 2016-09-27 | — | — | US | disclosed |
| US-9453038-B2 | Glucokinase activator compounds, compositions containing such compounds, and methods of treatment | MERCK SHARP & DOHME CORP. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150336991-A1 | NOVEL GLUCOKINASE ACTIVATOR COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2015-11-26 | — | — | US | disclosed |
| US-20150336991-A1 | NOVEL GLUCOKINASE ACTIVATOR COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2015-11-26 | — | — | US | disclosed |
| US-20150336991-A1 | NOVEL GLUCOKINASE ACTIVATOR COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2015-11-26 | — | — | US | disclosed |
| EP-2931734-A1 | NOVEL GLUCOKINASE ACTIVATOR COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT | Merck Sharp & Dohme Corp. (US) | 2015-10-21 | — | — | EP | disclosed |
| WO-2014099578-A1 | NOVEL GLUCOKINASE ACTIVATOR COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014099578-A1 | NOVEL GLUCOKINASE ACTIVATOR COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2014-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336991-A1 | NOVEL GLUCOKINASE ACTIVATOR COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT | GCK, GCKR, HK2 | ALDH1A1 1590/4885SMN1; SMN2 3353/4885SLC6A2 3663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.